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Cell therapy regimens are frequently compromised by
low-efficiency cell homing to therapeutic niches.
Improvements in this regard would enhance effectiveness
of clinically-applicable cell therapy. The major regulators
of tissue-specific cellular migration are chemokines and
therefore selection of therapeutic cellular populations for
appropriate chemokine receptor expression would
enhance tissue-homing competence. We have recently
shown that biotinylated ligands for chemokine receptors
can be used as efficient cell sorting reagents[1]. These
ligands have several advantages over antibodies, as they
can be chemically synthesized to the appropriate grade
for clinical use; produced and modified extremely quickly
and are generally not species-specific. Furthermore,
receptors are rapidly recycled post cell selection leaving
cells free to respond to chemokine gradients, and thereby
migrate to the required therapeutic site. We have applied
this technology to the improvement of dendritic cell
(DC) and T cell products for potential use as cellular
therapeutics. CCL19, a high-affinity ligand for CCR7, is
of particular interest in this field, as CCR7 expression by
DC is a marker of maturity and lymph node homing abil-
ity. Also, CCR7+ central memory T cells are the most
desired cell population for generation or engineering of
tumour-antigen-specific therapeutic responses. Here we
report the generation of biotinylated, chemically synthe-
sised, modified human CCL19 molecules for optimised
cell sorting. Our results demonstrate that these ligands
allow the efficient enrichment of mature, antigen-loaded
human or murine CCR7+ DC using a rapid and estab-
lished magnetic bead sorting strategy. CCR7+ murine
bone marrow-derived DC (BM-DC) isolated using this
GMP-compliant method display significantly improved
lymph-node homing ability in vivo over standard
(unsorted) BM-DC preparations. Using in vitro models,
such as murine OT-I, we also demonstrate the ability of
these sorted DC to efficiently generate both effector and
memory antigen-specific T cell responses. In conclusion,
we show that biotinylated ligands for chemokine receptors
constitute a novel, GMP-compliant cell sorting strategy
that could enhance the efficacy of existing clinical cell
therapy regimens.
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